| Molecular profiling in muscle‐invasive bladder cancer: more than the sum of its parts G Sjödahl, CL Jackson, JMS Bartlett, DR Siemens, DM Berman The Journal of pathology 247 (5), 563-573, 2019 | 79 | 2019 |
| A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancer PG Patel, T Wessel, A Kawashima, JBA Okello, T Jamaspishvili, ... The Prostate 79 (14), 1705-1714, 2019 | 32 | 2019 |
| Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint S Chenard, C Jackson, T Vidotto, L Chen, C Hardy, T Jamaspishvilli, ... European Urology Open Science 29, 50-58, 2021 | 17 | 2021 |
| Diagnostic and prognostic implications of a three‐antibody molecular subtyping algorithm for non‐muscle invasive bladder cancer CL Jackson, L Chen, CSC Hardy, KYM Ren, K Visram, VF Bratti, ... The Journal of Pathology: Clinical Research 8 (2), 143-154, 2022 | 10 | 2022 |
| Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers CSC Hardy, H Ghaedi, A Slotman, G Sjödahl, RJ Gooding, DM Berman, ... Journal of Histochemistry & Cytochemistry 70 (5), 357-375, 2022 | 6 | 2022 |
| Multimodal biomarkers that predict the presence of Gleason pattern 4: potential impact for active surveillance DM Berman, AY Lee, R Lesurf, PG Patel, W Ebrahimizadeh, J Bayani, ... The Journal of Urology 210 (2), 257-271, 2023 | 2 | 2023 |
| Quantitative Nuclear Grading: An Objective, Artificial Intelligence–Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma A Slotman, M Xu, K Lindale, C Hardy, D Winkowski, R Baird, L Chen, ... Laboratory Investigation 103 (7), 100155, 2023 | 2 | 2023 |
| Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy C Hesswani, CL Jackson, G Marcq, C Hardy, R Kool, JJ Mansure, F Brimo, ... European Urology Open Science 57, 22-29, 2023 | | 2023 |
| Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancer B Ravenscroft, P Yolmo, S Chenard, S Rahimi, K Pace, K Sachdeva, ... bioRxiv, 2023.10. 19.562817, 2023 | | 2023 |
| Quantitative Nuclear Grading: An Objective, Artificial IntelligenceeFacilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma A Slotman, M Xu, K Lindale, C Hardy, D Winkowski, R Baird, L Chen, ... LABORATORY INVESTIGATION 103 (7), 2023 | | 2023 |
| Abstract B046: Multimodal biomarkers that predict the presence of Gleason pattern 4: Potential impact for active surveillance AY Lee, DM Berman, R Lesurf, PG Patel, W Ebrahimizadeh, J Bayani, ... Cancer Research 83 (11_Supplement), B046-B046, 2023 | | 2023 |
| Automated Nuclear Size, Shape, and Mitotic Index Measurements that Objectively Distinguish Low-Grade from High-Grade Non-Invasive Papillary Urothelial Carcinoma A Slotman, M Xu, D Winkowski, C Hardy, L Chen, R Baird, C Jackson, ... LABORATORY INVESTIGATION 102 (SUPPL 1), 676-677, 2022 | | 2022 |
| M2 macrophages, B cells, and PD-L1 immune checkpoint protein exhibit sexual dimorphism in the outcomes of non-muscle invasive bladder cancer S Chenard, C Jackson, T Vidotto, L Chen, C Hardy, T Jamaspishvilli, ... The Journal of Immunology 206 (1_Supplement), 56.10-56.10, 2021 | | 2021 |
| PUNLMP and Low-Grade Noninvasive Papillary Urothelial Carcinoma Are Indistinguishable by Prognosis and Molecular Subtype C Jackson, L Chen, C Hardy, G Sjodahl, D Siemens, D Berman LABORATORY INVESTIGATION 101 (SUPPL 1), 570-571, 2021 | | 2021 |
| Immunohistochemical assays for bladder cancer molecular subtyping: Optimizing parsimony and performance using Lund taxonomy C Hardy, H Ghaedi, A Slotman, G Sjödahl, RJ Gooding, DM Berman, ... bioRxiv, 2021 | | 2021 |
| Prognostic Features of Non-muscle-invasive Bladder Cancer: Grade, Molecular Subtype and Tumour Immune Microenvironment CL Jackson Queen's University (Canada), 2021 | | 2021 |
| Predictive and Prognostic Performance of IHC3 Immunohistochemistry-based Molecular Subtyping in Muscle-Invasive Bladder Cancer CH Hardy, CL Jackson, L Chen, G Sjödahl, RJ Gooding, DM Berman Urologic Oncology: Seminars and Original Investigations 38 (12), 906, 2020 | | 2020 |
| Investigating sexual dimorphism in the tumour immune microenvironment of non-muscle invasive bladder cancer S Chenard, C Jackson, T Vidotto, L Chen, C Hardy, T Jamaspishvilli, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 908, 2020 | | 2020 |
| A simple immunohistochemical algorithm to evaluate molecular subtypes and clinical associations in non-muscle invasive bladder cancer. CL Jackson, L Chen, KYM Ren, K Visram, R Siemens, G Sjodahl, ... CLINICAL CANCER RESEARCH 26 (15), 51-52, 2020 | | 2020 |
| Abstract B10: A simple immunohistochemical algorithm to evaluate molecular subtypes and clinical associations in non-muscle invasive bladder cancer CL Jackson, L Chen, KYM Ren, K Visram, R Siemens, G Sjödahl, ... Clinical Cancer Research 26 (15 Supplement), B10-B10, 2020 | | 2020 |
